INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 428m ago
HOUSE PTR27m ago
SEC 13F27m ago
ROBINHOOD CHAIN27m ago
Corporate insider
PK

Piskel Kyle

Chief Financial OfficerCIK 0001780662

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 2
Max Insider Score37
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
7
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
4,290 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Adaptive Biotechnologies CorpChief Financial Officer · Dec 2, 2025
0
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M
$52K
4,290 sh
Jan 12, 2026
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC FORM 4

Evidence

19
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$77K
4,290 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

37
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$3.17M
162.8K sh
Nov 28, 2025Dec 2, 2025
traded Nov 28, 2025
+4dSEC FORM 4

Evidence

0
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
94.4K sh
Nov 28, 2025Dec 2, 2025
traded Nov 28, 2025
+4dSEC FORM 4

Evidence

2
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$78K
12.0K sh
Nov 28, 2025Dec 2, 2025
traded Nov 28, 2025
+4dSEC FORM 4

Evidence

0
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
12.0K sh
Nov 28, 2025Dec 2, 2025
traded Nov 28, 2025
+4dSEC FORM 4

Evidence

0
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
3,750 sh
Nov 28, 2025Dec 2, 2025
traded Nov 28, 2025
+4dSEC FORM 4

Evidence

0
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$29K
3,750 sh
Nov 28, 2025Dec 2, 2025
traded Nov 28, 2025
+4dSEC FORM 4

Evidence

16
PK
Piskel KyleChief Financial Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$1.15M
94.4K sh
Nov 28, 2025Dec 2, 2025
traded Nov 28, 2025
+4dSEC FORM 4

Evidence